PT1137792E - Vector recombinado que exprime moléculas costimulantes múltiplas e as suas utilizações - Google Patents
Vector recombinado que exprime moléculas costimulantes múltiplas e as suas utilizações Download PDFInfo
- Publication number
- PT1137792E PT1137792E PT99958951T PT99958951T PT1137792E PT 1137792 E PT1137792 E PT 1137792E PT 99958951 T PT99958951 T PT 99958951T PT 99958951 T PT99958951 T PT 99958951T PT 1137792 E PT1137792 E PT 1137792E
- Authority
- PT
- Portugal
- Prior art keywords
- cells
- antigen
- recombinant vector
- cell
- fic
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims abstract description 60
- 239000002537 cosmetic Substances 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 46
- 239000000427 antigen Substances 0.000 claims abstract description 45
- 108091007433 antigens Proteins 0.000 claims abstract description 45
- 102000036639 antigens Human genes 0.000 claims abstract description 45
- 230000000139 costimulatory effect Effects 0.000 claims abstract description 23
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 14
- 230000001900 immune effect Effects 0.000 claims abstract description 8
- 229960005486 vaccine Drugs 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract 8
- 210000004443 dendritic cell Anatomy 0.000 claims abstract 6
- 230000002163 immunogen Effects 0.000 claims abstract 3
- 201000011510 cancer Diseases 0.000 claims abstract 2
- 244000000010 microbial pathogen Species 0.000 claims abstract 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 230000035755 proliferation Effects 0.000 claims description 13
- 241000700605 Viruses Species 0.000 claims description 11
- 108010084313 CD58 Antigens Proteins 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 241001529936 Murinae Species 0.000 claims description 3
- 210000000987 immune system Anatomy 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims 9
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 8
- 208000007089 vaccinia Diseases 0.000 claims 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 102100037850 Interferon gamma Human genes 0.000 claims 4
- 108010074328 Interferon-gamma Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 150000001413 amino acids Chemical group 0.000 claims 3
- 230000003053 immunization Effects 0.000 claims 3
- 238000002649 immunization Methods 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- 241001529453 unidentified herpesvirus Species 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 241000271566 Aves Species 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 108010062580 Concanavalin A Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 241000233866 Fungi Species 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 241000713666 Lentivirus Species 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 108010008707 Mucin-1 Proteins 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 2
- 230000009089 cytolysis Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 206010020718 hyperplasia Diseases 0.000 claims 2
- 230000002390 hyperplastic effect Effects 0.000 claims 2
- 230000001965 increasing effect Effects 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 244000045947 parasite Species 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 210000000952 spleen Anatomy 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- -1 197 gpt Proteins 0.000 claims 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 1
- 108010082808 4-1BB Ligand Proteins 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims 1
- 241000710929 Alphavirus Species 0.000 claims 1
- 241000228212 Aspergillus Species 0.000 claims 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100022002 CD59 glycoprotein Human genes 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 108700037122 EWS-FLI fusion Proteins 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 208000037262 Hepatitis delta Diseases 0.000 claims 1
- 241000724709 Hepatitis delta virus Species 0.000 claims 1
- 241000709721 Hepatovirus A Species 0.000 claims 1
- 201000002563 Histoplasmosis Diseases 0.000 claims 1
- 241001272567 Hominoidea Species 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims 1
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 241000701372 Iridovirus Species 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims 1
- 241000589248 Legionella Species 0.000 claims 1
- 208000007764 Legionnaires' Disease Diseases 0.000 claims 1
- 241000222722 Leishmania <genus> Species 0.000 claims 1
- 241000186781 Listeria Species 0.000 claims 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 102100023123 Mucin-16 Human genes 0.000 claims 1
- 102100034263 Mucin-2 Human genes 0.000 claims 1
- 108010008705 Mucin-2 Proteins 0.000 claims 1
- 241000186359 Mycobacterium Species 0.000 claims 1
- 241000187654 Nocardia Species 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 241001631646 Papillomaviridae Species 0.000 claims 1
- 241000709664 Picornaviridae Species 0.000 claims 1
- 241000224016 Plasmodium Species 0.000 claims 1
- 241000233872 Pneumocystis carinii Species 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100029216 SLAM family member 5 Human genes 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 241000287219 Serinus canaria Species 0.000 claims 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 claims 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 claims 1
- 102000006601 Thymidine Kinase Human genes 0.000 claims 1
- 108020004440 Thymidine kinase Proteins 0.000 claims 1
- 241000223997 Toxoplasma gondii Species 0.000 claims 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102000003425 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims 1
- 230000001464 adherent effect Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000003466 anti-cipated effect Effects 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 201000010284 hepatitis E Diseases 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 101150066555 lacZ gene Proteins 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 1
- 239000003226 mitogen Substances 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 230000001855 preneoplastic effect Effects 0.000 claims 1
- 238000007790 scraping Methods 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- 229940104230 thymidine Drugs 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 230000006870 function Effects 0.000 abstract description 4
- 230000004913 activation Effects 0.000 abstract description 3
- 230000006044 T cell activation Effects 0.000 abstract description 2
- 230000000711 cancerogenic effect Effects 0.000 abstract 1
- 210000004988 splenocyte Anatomy 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- 102100036008 CD48 antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 101150114927 MUC1 gene Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4264—Cancer antigens from embryonic or fetal origin
- A61K40/4266—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K40/4275—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70528—CD58
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/58—Prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Transplantation (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11158298P | 1998-12-09 | 1998-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1137792E true PT1137792E (pt) | 2007-08-10 |
Family
ID=22339329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT99958951T PT1137792E (pt) | 1998-12-09 | 1999-11-12 | Vector recombinado que exprime moléculas costimulantes múltiplas e as suas utilizações |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1137792B9 (https=) |
| JP (2) | JP4409097B2 (https=) |
| AT (1) | ATE361988T1 (https=) |
| AU (1) | AU774076C (https=) |
| CA (2) | CA2678259C (https=) |
| CY (1) | CY1107698T1 (https=) |
| DE (1) | DE69936061T2 (https=) |
| DK (1) | DK1137792T3 (https=) |
| ES (1) | ES2286902T3 (https=) |
| PT (1) | PT1137792E (https=) |
| WO (1) | WO2000034494A1 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6756038B1 (en) * | 1997-10-10 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Agonist and antagonist peptides of carcinoembryonic antigen (CEA) |
| DE10048710A1 (de) * | 1999-09-27 | 2001-10-04 | Gabriele Pecher | Pharmazeutische Zusammensetzung zur Behandlung und Prophylaxe von humanen Tumoren, die das Tumorantigen Muzin und/oder das Carcinoembryonale Antigen (CEA) exprimieren und ihre Verwendung |
| CA2388337C (en) * | 1999-10-22 | 2013-01-08 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
| US7179462B2 (en) | 2000-06-02 | 2007-02-20 | University Of Connecticut Health Center | α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof |
| EP1286693A4 (en) | 2000-06-02 | 2005-07-13 | Univ Connecticut Health Ct | COMPLEXES OF ALPHA (2) MACROGLOBULIN AND ANTIGENIC MOLECULES FOR USE IN IMMUNOTHERAPY |
| US7186515B1 (en) | 2000-06-02 | 2007-03-06 | University Of Connecticut Health Center | Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof |
| EP1305414A2 (en) * | 2000-07-31 | 2003-05-02 | Aventis Pasteur Limited | Modified cea and uses thereof |
| WO2002018954A2 (en) | 2000-08-30 | 2002-03-07 | Chemocentryx, Inc. | Inhibition of cmv infection and dissemination |
| EP2336339A3 (en) | 2000-09-25 | 2011-09-14 | The Regents of the University of Michigan | Production of viral vectors |
| CA2437201C (en) | 2001-02-02 | 2008-11-18 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
| WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| US7414032B2 (en) | 2001-06-25 | 2008-08-19 | Immunofrontier, Inc. | Vaccine comprising a polynucleotide encoding an antigen recognized by a CD4+ helper T-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a CD8+ CTL |
| KR101455222B1 (ko) | 2002-12-16 | 2014-10-31 | 글로브이뮨 | 면역 요법으로서의 효모계 백신 |
| JP2007503834A (ja) * | 2003-09-05 | 2007-03-01 | サノフィ パストゥール リミテッド | 黒色腫用の多抗原ベクター |
| CA2550583C (en) * | 2003-10-08 | 2013-01-15 | Sanofi Pasteur, Inc. | Modified cea /b7 vector |
| WO2005046622A2 (en) | 2003-11-12 | 2005-05-26 | Therion Biologics Corporation | Custom vectors for treating and preventing pancreatic cancer |
| DK1694364T3 (da) * | 2003-11-12 | 2014-07-21 | Us Government | System til behandling og forebyggelse af brystcancer |
| WO2005068640A2 (en) * | 2003-12-23 | 2005-07-28 | Aventis Pasteur, Inc. | Modified ksa and uses thereof |
| WO2006004362A1 (en) * | 2004-07-03 | 2006-01-12 | Mogam Biotechnology Research Institute | Supertype epitopes, oligonucleotides coding the same which induce effective ctl response against hcv and the use thereof |
| US7785875B2 (en) | 2004-07-03 | 2010-08-31 | Mogam Biotechnology Research Institute | Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same |
| ES2313807B1 (es) * | 2005-07-30 | 2009-12-23 | Consejo Superior De Investigaciones Cientificas | Vectores recombinantes basados en el virus vaccinia modificado de ankara (mva) como vacunas contra la leishmaniasis. |
| EP1792996A1 (en) * | 2005-12-01 | 2007-06-06 | Consejo Superior de Investigaciones Cientificas | Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV) |
| SI2856876T1 (en) | 2007-03-30 | 2018-04-30 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| DK2170384T3 (en) | 2007-07-02 | 2016-07-25 | Etubics Corp | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination |
| AU2008312444B2 (en) * | 2007-10-18 | 2014-02-06 | Bavarian Nordic A/S | Use of MVA to treat prostate cancer |
| WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
| US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| WO2010050913A1 (en) * | 2008-10-31 | 2010-05-06 | The Brigham And Women's Hospital, Inc. | Vaccination with poxvirus vectors via mechanical epidermal disruption |
| MX2011010977A (es) | 2009-04-17 | 2012-02-29 | Us Health | Composiciones inmunoterapeuticas combinadas contra cancer y metodos. |
| SG10201607663YA (en) | 2011-08-17 | 2016-11-29 | Globeimmune Inc | Yeast-muc1 immunotherapeutic compositions and uses thereof |
| US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| CA2914790C (en) | 2013-06-14 | 2024-02-27 | Psioxus Therapeutics Limited | A dosing regime and formulations for type b adenoviruses |
| HUE035875T2 (hu) | 2013-10-25 | 2018-06-28 | Psioxus Therapeutics Ltd | Heterológ géneket tartalmazó onkolitikus adenovírusok |
| UA127337C2 (uk) * | 2013-11-28 | 2023-07-26 | Баваріан Нордік А/С | Рекомбінантний поксвірус для індукції посиленої імунної відповіді та його застосування |
| JP5917626B2 (ja) * | 2014-07-28 | 2016-05-18 | トレムアールエックス， インコーポレイテッド | 機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種 |
| CN107406857B (zh) * | 2015-01-09 | 2021-06-29 | 埃图比克斯公司 | 用于联合免疫治疗的方法和组合物 |
| AU2016205208A1 (en) | 2015-01-09 | 2017-07-06 | Etubics Corporation | Methods and compositions for ebola virus vaccination |
| US11149087B2 (en) | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| HRP20200439T1 (hr) | 2015-04-30 | 2020-06-12 | Psioxus Therapeutics Limited | Onkolitički adenovirus koji kodira protein b7 |
| BR112018012180A2 (pt) | 2015-12-17 | 2018-12-04 | Psioxus Therapeutics Ltd | vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr |
| CN109312364A (zh) * | 2016-03-18 | 2019-02-05 | 河谷细胞有限公司 | 用于感染树突状细胞的多模式载体 |
| CN109890408A (zh) * | 2016-05-27 | 2019-06-14 | 埃特彼塞斯公司 | 新表位疫苗组合物及其使用方法 |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| IL303187A (en) | 2016-08-29 | 2023-07-01 | Akamis Bio Ltd | Adenovirus with bispecific T cell activator |
| CA3092860A1 (en) * | 2018-03-06 | 2019-09-12 | Pepvax, Inc. | Nucleic acid molecules and methods of using the same |
| US20210290708A1 (en) | 2018-09-21 | 2021-09-23 | Nantcell, Inc. | Methods and compositions for modulating myeloid-derived suppressor cells |
| GB202010095D0 (en) * | 2020-07-01 | 2020-08-12 | Tcer Ab | Immunotherapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR960701988A (ko) * | 1993-04-20 | 1996-03-28 | 윌리엄 에스. 로빈슨 | 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents) |
| DE69519521T2 (de) * | 1994-10-03 | 2001-06-28 | The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health | Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus |
| AU731860B2 (en) * | 1996-07-25 | 2001-04-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant pox virus for immunization against tumor-associated antigens |
-
1999
- 1999-11-12 DK DK99958951T patent/DK1137792T3/da active
- 1999-11-12 ES ES99958951T patent/ES2286902T3/es not_active Expired - Lifetime
- 1999-11-12 WO PCT/US1999/026866 patent/WO2000034494A1/en not_active Ceased
- 1999-11-12 CA CA2678259A patent/CA2678259C/en not_active Expired - Lifetime
- 1999-11-12 CA CA002354024A patent/CA2354024C/en not_active Expired - Lifetime
- 1999-11-12 AU AU16218/00A patent/AU774076C/en not_active Expired
- 1999-11-12 EP EP99958951A patent/EP1137792B9/en not_active Expired - Lifetime
- 1999-11-12 DE DE69936061T patent/DE69936061T2/de not_active Expired - Lifetime
- 1999-11-12 PT PT99958951T patent/PT1137792E/pt unknown
- 1999-11-12 AT AT99958951T patent/ATE361988T1/de active
- 1999-11-12 JP JP2000586927A patent/JP4409097B2/ja not_active Expired - Lifetime
-
2007
- 2007-07-13 CY CY20071100941T patent/CY1107698T1/el unknown
-
2009
- 2009-08-12 JP JP2009187330A patent/JP5254153B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CY1107698T1 (el) | 2013-04-18 |
| AU774076B2 (en) | 2004-06-17 |
| WO2000034494A1 (en) | 2000-06-15 |
| DK1137792T3 (da) | 2007-09-10 |
| ES2286902T3 (es) | 2007-12-01 |
| CA2678259C (en) | 2016-10-18 |
| CA2678259A1 (en) | 2000-06-15 |
| CA2354024A1 (en) | 2000-06-15 |
| DE69936061D1 (de) | 2007-06-21 |
| JP2002531133A (ja) | 2002-09-24 |
| ATE361988T1 (de) | 2007-06-15 |
| EP1137792A1 (en) | 2001-10-04 |
| JP2009254390A (ja) | 2009-11-05 |
| AU774076C (en) | 2005-04-14 |
| DE69936061T2 (de) | 2008-01-17 |
| EP1137792B9 (en) | 2007-12-12 |
| JP5254153B2 (ja) | 2013-08-07 |
| JP4409097B2 (ja) | 2010-02-03 |
| AU1621800A (en) | 2000-06-26 |
| EP1137792B1 (en) | 2007-05-09 |
| CA2354024C (en) | 2009-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1137792E (pt) | Vector recombinado que exprime moléculas costimulantes múltiplas e as suas utilizações | |
| US7211432B2 (en) | Recombinant vector expressing multiple costimulatory molecules and uses thereof | |
| JP4059920B2 (ja) | 癌自己関連抗原特異的ヒト細胞障害性ｔ細胞の産生とその使用 | |
| JP3907698B2 (ja) | 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物 | |
| AU712714B2 (en) | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule B7 gene in a recombinant virus expressing system | |
| US6187307B1 (en) | Cancer immunotherapy with semi-allogeneic cells | |
| JP2004507231A (ja) | 免疫応答を向上させるための、ｇｍ−ｃｓｆを発現する組換え非−複製性ウィルスおよびその使用 | |
| PT1249490E (pt) | Activação de células t citotóxicas in vitro | |
| Kaufman et al. | Strategies for cancer therapy using carcinoembryonic antigen vaccines | |
| US20070048860A1 (en) | Carcinoembryonic antigen (CEA) peptides | |
| US20020155093A1 (en) | Method for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen | |
| US20050100558A1 (en) | Heterologous boosting immunizations | |
| CA2252406A1 (en) | Heterologous boosting immunizations | |
| EP1865065A1 (en) | A recombinant vector expressing multiple costimulatory molecules and uses thereof | |
| Ghose et al. | Immunogenicity of whole-cell tumor preparations infected with the ALVAC viral vector |